Premium
Increased Dosage of DYRK1A and Brain Volumetric Alterations in a YAC Model of Partial Trisomy 21
Author(s) -
Sebrié Catherine,
Chabert Caroline,
Ledru Aurélie,
Guedj Fayçal,
Po Chrystelle,
Smith Desmond J.,
Rubin Edward,
Rivals Isabelle,
Beloeil JeanClaude,
Gillet Brigitte,
Delabar JeanMaurice
Publication year - 2008
Publication title -
the anatomical record: advances in integrative anatomy and evolutionary biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.678
H-Index - 62
eISSN - 1932-8494
pISSN - 1932-8486
DOI - 10.1002/ar.20640
Subject(s) - dyrk1a , trisomy , brain size , biology , threonine , thalamus , genetically modified mouse , phenotype , transgene , endocrinology , medicine , gene , magnetic resonance imaging , serine , neuroscience , microbiology and biotechnology , genetics , phosphorylation , radiology
Abstract A yeast artificial chromosome (YAC) transgenic murine model of partial trisomy 21 overexpressing five human genes—including DYRK1A , which encodes a serine threonine kinase involved in cell cycle control—has been shown to present an increase in brain weight. We analyzed this new phenotype by measuring total and regional brain volumes at different ages, using a 7 Tesla magnetic resonance imaging volumetric approach. Volumetric measurements showed a total volume increase of 13.6% in adult mice. Changes in brain morphogenesis were already visible at a very early postnatal stage (postnatal days 2–7). Region‐specific changes were characterized from postnatal day 15 to 5 months. These results, made it possible to define region‐specific effects of DYRK1A overexpression, with the strongest increase seen in the thalamus–hypothalamus area (24%). Anat Rec, 291:254–262, 2008. © 2008 Wiley‐Liss, Inc.